-
- Liam R. Brunham
- From the Centre for Molecular Medicine and Therapeutics and Child and Family Research Institute (L.R.B., R.R.S., N.B., M.H.K., M.R.H.), University of British Columbia, Vancouver, Canada; the Department of Pathology/Section on Lipid Sciences (M.D., J.M.T., J.S.P.), Wake Forest University Health Sciences, Winston-Salem, NC; Institut Pasteur de Lille, Inserm U545 (C.F., J.C.F., B.S.), Université de Lille, France; and the iCAPTURE Centre (A.S., B.M.), St Paul’s Hospital/Providence Health Care,...
-
- Roshni R. Singaraja
- From the Centre for Molecular Medicine and Therapeutics and Child and Family Research Institute (L.R.B., R.R.S., N.B., M.H.K., M.R.H.), University of British Columbia, Vancouver, Canada; the Department of Pathology/Section on Lipid Sciences (M.D., J.M.T., J.S.P.), Wake Forest University Health Sciences, Winston-Salem, NC; Institut Pasteur de Lille, Inserm U545 (C.F., J.C.F., B.S.), Université de Lille, France; and the iCAPTURE Centre (A.S., B.M.), St Paul’s Hospital/Providence Health Care,...
-
- MyNgan Duong
- From the Centre for Molecular Medicine and Therapeutics and Child and Family Research Institute (L.R.B., R.R.S., N.B., M.H.K., M.R.H.), University of British Columbia, Vancouver, Canada; the Department of Pathology/Section on Lipid Sciences (M.D., J.M.T., J.S.P.), Wake Forest University Health Sciences, Winston-Salem, NC; Institut Pasteur de Lille, Inserm U545 (C.F., J.C.F., B.S.), Université de Lille, France; and the iCAPTURE Centre (A.S., B.M.), St Paul’s Hospital/Providence Health Care,...
-
- Jenelle M. Timmins
- From the Centre for Molecular Medicine and Therapeutics and Child and Family Research Institute (L.R.B., R.R.S., N.B., M.H.K., M.R.H.), University of British Columbia, Vancouver, Canada; the Department of Pathology/Section on Lipid Sciences (M.D., J.M.T., J.S.P.), Wake Forest University Health Sciences, Winston-Salem, NC; Institut Pasteur de Lille, Inserm U545 (C.F., J.C.F., B.S.), Université de Lille, France; and the iCAPTURE Centre (A.S., B.M.), St Paul’s Hospital/Providence Health Care,...
-
- Catherine Fievet
- From the Centre for Molecular Medicine and Therapeutics and Child and Family Research Institute (L.R.B., R.R.S., N.B., M.H.K., M.R.H.), University of British Columbia, Vancouver, Canada; the Department of Pathology/Section on Lipid Sciences (M.D., J.M.T., J.S.P.), Wake Forest University Health Sciences, Winston-Salem, NC; Institut Pasteur de Lille, Inserm U545 (C.F., J.C.F., B.S.), Université de Lille, France; and the iCAPTURE Centre (A.S., B.M.), St Paul’s Hospital/Providence Health Care,...
-
- Nagat Bissada
- From the Centre for Molecular Medicine and Therapeutics and Child and Family Research Institute (L.R.B., R.R.S., N.B., M.H.K., M.R.H.), University of British Columbia, Vancouver, Canada; the Department of Pathology/Section on Lipid Sciences (M.D., J.M.T., J.S.P.), Wake Forest University Health Sciences, Winston-Salem, NC; Institut Pasteur de Lille, Inserm U545 (C.F., J.C.F., B.S.), Université de Lille, France; and the iCAPTURE Centre (A.S., B.M.), St Paul’s Hospital/Providence Health Care,...
-
- Martin H. Kang
- From the Centre for Molecular Medicine and Therapeutics and Child and Family Research Institute (L.R.B., R.R.S., N.B., M.H.K., M.R.H.), University of British Columbia, Vancouver, Canada; the Department of Pathology/Section on Lipid Sciences (M.D., J.M.T., J.S.P.), Wake Forest University Health Sciences, Winston-Salem, NC; Institut Pasteur de Lille, Inserm U545 (C.F., J.C.F., B.S.), Université de Lille, France; and the iCAPTURE Centre (A.S., B.M.), St Paul’s Hospital/Providence Health Care,...
-
- Amrit Samra
- From the Centre for Molecular Medicine and Therapeutics and Child and Family Research Institute (L.R.B., R.R.S., N.B., M.H.K., M.R.H.), University of British Columbia, Vancouver, Canada; the Department of Pathology/Section on Lipid Sciences (M.D., J.M.T., J.S.P.), Wake Forest University Health Sciences, Winston-Salem, NC; Institut Pasteur de Lille, Inserm U545 (C.F., J.C.F., B.S.), Université de Lille, France; and the iCAPTURE Centre (A.S., B.M.), St Paul’s Hospital/Providence Health Care,...
-
- Jean-Charles Fruchart
- From the Centre for Molecular Medicine and Therapeutics and Child and Family Research Institute (L.R.B., R.R.S., N.B., M.H.K., M.R.H.), University of British Columbia, Vancouver, Canada; the Department of Pathology/Section on Lipid Sciences (M.D., J.M.T., J.S.P.), Wake Forest University Health Sciences, Winston-Salem, NC; Institut Pasteur de Lille, Inserm U545 (C.F., J.C.F., B.S.), Université de Lille, France; and the iCAPTURE Centre (A.S., B.M.), St Paul’s Hospital/Providence Health Care,...
-
- Bruce McManus
- From the Centre for Molecular Medicine and Therapeutics and Child and Family Research Institute (L.R.B., R.R.S., N.B., M.H.K., M.R.H.), University of British Columbia, Vancouver, Canada; the Department of Pathology/Section on Lipid Sciences (M.D., J.M.T., J.S.P.), Wake Forest University Health Sciences, Winston-Salem, NC; Institut Pasteur de Lille, Inserm U545 (C.F., J.C.F., B.S.), Université de Lille, France; and the iCAPTURE Centre (A.S., B.M.), St Paul’s Hospital/Providence Health Care,...
-
- Bart Staels
- From the Centre for Molecular Medicine and Therapeutics and Child and Family Research Institute (L.R.B., R.R.S., N.B., M.H.K., M.R.H.), University of British Columbia, Vancouver, Canada; the Department of Pathology/Section on Lipid Sciences (M.D., J.M.T., J.S.P.), Wake Forest University Health Sciences, Winston-Salem, NC; Institut Pasteur de Lille, Inserm U545 (C.F., J.C.F., B.S.), Université de Lille, France; and the iCAPTURE Centre (A.S., B.M.), St Paul’s Hospital/Providence Health Care,...
-
- John S. Parks
- From the Centre for Molecular Medicine and Therapeutics and Child and Family Research Institute (L.R.B., R.R.S., N.B., M.H.K., M.R.H.), University of British Columbia, Vancouver, Canada; the Department of Pathology/Section on Lipid Sciences (M.D., J.M.T., J.S.P.), Wake Forest University Health Sciences, Winston-Salem, NC; Institut Pasteur de Lille, Inserm U545 (C.F., J.C.F., B.S.), Université de Lille, France; and the iCAPTURE Centre (A.S., B.M.), St Paul’s Hospital/Providence Health Care,...
-
- Michael R. Hayden
- From the Centre for Molecular Medicine and Therapeutics and Child and Family Research Institute (L.R.B., R.R.S., N.B., M.H.K., M.R.H.), University of British Columbia, Vancouver, Canada; the Department of Pathology/Section on Lipid Sciences (M.D., J.M.T., J.S.P.), Wake Forest University Health Sciences, Winston-Salem, NC; Institut Pasteur de Lille, Inserm U545 (C.F., J.C.F., B.S.), Université de Lille, France; and the iCAPTURE Centre (A.S., B.M.), St Paul’s Hospital/Providence Health Care,...
説明
<jats:p> <jats:bold> <jats:italic>Objective—</jats:italic> </jats:bold> The ATP-binding cassette transporter, subfamily A, member 1 ( <jats:italic>ABCA1</jats:italic> ) plays a key role in HDL cholesterol metabolism. However, the role of <jats:italic>ABCA1</jats:italic> in modulating susceptibility to atherosclerosis is controversial. </jats:p> <jats:p> <jats:bold> <jats:italic>Methods and Results—</jats:italic> </jats:bold> We investigated the role of <jats:italic>ABCA1</jats:italic> in atherosclerosis using a combination of overexpression and selective deletion models. First, we examined the effect of transgenic overexpression of a full-length human <jats:italic>ABCA1</jats:italic> -containing bacterial artificial chromosome (BAC) in the presence or absence of the endogenous mouse <jats:italic>Abca1</jats:italic> gene. <jats:italic>ABCA1</jats:italic> overexpression in the atherosclerosis-susceptible <jats:italic>Ldlr</jats:italic> <jats:sup>−/−</jats:sup> background significantly reduced the development of atherosclerosis in both the presence and absence of mouse <jats:italic>Abca1</jats:italic> . Next, we used mice with tissue-specific inactivation of <jats:italic>Abca1</jats:italic> to dissect the discrete roles of <jats:italic>Abca1</jats:italic> in different tissues on susceptibility to atherosclerosis. On the <jats:italic>Apoe</jats:italic> <jats:sup>−/−</jats:sup> background, mice lacking hepatic <jats:italic>Abca1</jats:italic> had significantly reduced HDL cholesterol and accelerated atherosclerosis, indicating that the liver is an important site at which <jats:italic>Abca1</jats:italic> plays an antiatherogenic role. In contrast, mice with macrophage-specific inactivation of <jats:italic>Abca1</jats:italic> on the <jats:italic>Ldlr</jats:italic> <jats:sup>−/−</jats:sup> background displayed no change in atherosclerotic lesion area. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusions—</jats:italic> </jats:bold> These data indicate that physiological expression of <jats:italic>Abca1</jats:italic> modulates the susceptibility to atherosclerosis and establish hepatic <jats:italic>Abca1</jats:italic> expression as an important site of atheroprotection. In contrast, we show that selective deletion of macrophage <jats:italic>Abca1</jats:italic> does not significantly modulate atherogenesis. </jats:p>
収録刊行物
-
- Arteriosclerosis, Thrombosis, and Vascular Biology
-
Arteriosclerosis, Thrombosis, and Vascular Biology 29 (4), 548-554, 2009-04
Ovid Technologies (Wolters Kluwer Health)